ETV1 Human Pre-designed siRNA Set A contains three designed siRNAs for ETV1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ETV2 Human Pre-designed siRNA Set A contains three designed siRNAs for ETV2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ETV3 Human Pre-designed siRNA Set A contains three designed siRNAs for ETV3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ETV4 Human Pre-designed siRNA Set A contains three designed siRNAs for ETV4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ETV5 Human Pre-designed siRNA Set A contains three designed siRNAs for ETV5 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ETV6 Human Pre-designed siRNA Set A contains three designed siRNAs for ETV6 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ETV7 Human Pre-designed siRNA Set A contains three designed siRNAs for ETV7 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Eugenol acetate-d3 is deuterated labeled Decyl aldehyde (HY-W012570). Decyl aldehyde is a simple ten-carbon aldehyde. Decyl aldehyde is a bacterial luciferase substrate.

Eugenol/BSA is one of protein/peptide and small molecule drug conjugates (PDCs), consisting of Eugenol (HY-N0337) and BSA. PCDs are promising targeted therapeutics with better cell permeability and drug selectivity than antibody-drug conjugates (ADCs). PDCs have been widely used in research on cancer, COVID-19, and metabolic diseases[1].

Euphoscopin B (compound 5) is a cytotoxic macrocyclic diterpene isolated from Euphorbia helioscopia L[1].

EVA1A Human Pre-designed siRNA Set A contains three designed siRNAs for EVA1A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

EVC Human Pre-designed siRNA Set A contains three designed siRNAs for EVC gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

EVC2 Human Pre-designed siRNA Set A contains three designed siRNAs for EVC2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Everolimus (Standard) is the analytical standard of Everolimus. This product is intended for research and analytical applications. Everolimus (RAD001) is a Rapamycin (HY-10219) derivative and a potent, selective and orally active mTOR1 inhibitor. Everolimus binds to FKBP-12 to generate an immunosuppressive complex. Everolimus inhibits tumor cells proliferation and induces cell apoptosis and autophagy. Everolimus has […]

EVI2A Human Pre-designed siRNA Set A contains three designed siRNAs for EVI2A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

EVI2B Human Pre-designed siRNA Set A contains three designed siRNAs for EVI2B gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

EVI5 Human Pre-designed siRNA Set A contains three designed siRNAs for EVI5 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

EVL Human Pre-designed siRNA Set A contains three designed siRNAs for EVL gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Evobrutinib (M2951) is an orally active, potent, highly selective and irreversibly covalent BTK inhibitor, with an IC50 of 8.9 nM. Evobrutinib (M2951) can be used for the research of autoimmune diseases[1].

Evobrutinib (M2951) is an orally active, potent, highly selective and irreversibly covalent BTK inhibitor, with an IC50 of 8.9 nM. Evobrutinib (M2951) can be used for the research of autoimmune diseases[1].

Evobrutinib (M2951) is an orally active, potent, highly selective and irreversibly covalent BTK inhibitor, with an IC50 of 8.9 nM. Evobrutinib (M2951) can be used for the research of autoimmune diseases[1].

Evobrutinib (M2951) is an orally active, potent, highly selective and irreversibly covalent BTK inhibitor, with an IC50 of 8.9 nM. Evobrutinib (M2951) can be used for the research of autoimmune diseases[1].

Evobrutinib (M2951) is an orally active, potent, highly selective and irreversibly covalent BTK inhibitor, with an IC50 of 8.9 nM. Evobrutinib (M2951) can be used for the research of autoimmune diseases[1].

Evobrutinib (M2951) is an orally active, potent, highly selective and irreversibly covalent BTK inhibitor, with an IC50 of 8.9 nM. Evobrutinib (M2951) can be used for the research of autoimmune diseases[1].

EVPL Human Pre-designed siRNA Set A contains three designed siRNAs for EVPL gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

EVX1 Human Pre-designed siRNA Set A contains three designed siRNAs for EVX1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

EVX2 Human Pre-designed siRNA Set A contains three designed siRNAs for EVX2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

EWSR1 Human Pre-designed siRNA Set A contains three designed siRNAs for EWSR1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Exatecan analogue 1 (Icp-3) is a Exatecan (HY-13631) analogue. Exatecan analogue 1 can be used in the synthesis of antibody-drug conjugates (ADCs)[1]

Exatecan-amide-bicyclo[1.1.1]pentan-1-ol (Compound 79) is an exatecan (HY-13631) derivative that can be used as a payload in drug conjugates. Exatecan-amide-bicyclo[1.1.1]pentan-1-ol has significant inhibitory activity against a variety of tumor cell lines[1].

Exatecan-amide-bicyclo[1.1.1]pentan-1-ylmethanol (compound 45) is a camptothecin compound that can inhibit cell proliferation, with an IC50 of 2.92 ng/mL for MDA‑MB‑468 cells. Exatecan-amide-bicyclo[1.1.1]pentan-1-ylmethanol can be used for the research of cancer[1].

Exatecan-amide-CH2-O-CH2-CH2-OH (Compound 4) is a derivative of Exatecan (HY-13631). Exatecan-amide-CH2-O-CH2-CH2-OH can be used for the research of cell proliferative diseases such as cancer[1].

EXD1 Human Pre-designed siRNA Set A contains three designed siRNAs for EXD1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

EXD2 Human Pre-designed siRNA Set A contains three designed siRNAs for EXD2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

EXD3 Human Pre-designed siRNA Set A contains three designed siRNAs for EXD3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Exemestane-13C,d2 is 13C and deuterated labeled Exemestane (HY-13632). Exemestane (FCE 24304) is a selective, irreversible and orally active steroidal aromatase inhibitor with IC50s of 30 nM and 40 nM for human placental and rat ovarian aromatase, respectively. Exemestane can be used for hormone-dependent breast cancer research[1][2].

Exicorilant (CORT 125281) is a selective and oral active glucocorticoid receptor (GR) antagonist, with a Ki value of 7 nM[1]. Exicorilant (CORT 125281) has potential to overcome adiposity, glucose intolerance and dyslipidaemia[2].

Exicorilant (CORT 125281) is a selective and oral active glucocorticoid receptor (GR) antagonist, with a Ki value of 7 nM[1]. Exicorilant (CORT 125281) has potential to overcome adiposity, glucose intolerance and dyslipidaemia[2].

Exicorilant (CORT 125281) is a selective and oral active glucocorticoid receptor (GR) antagonist, with a Ki value of 7 nM[1]. Exicorilant (CORT 125281) has potential to overcome adiposity, glucose intolerance and dyslipidaemia[2].

Exicorilant (CORT 125281) is a selective and oral active glucocorticoid receptor (GR) antagonist, with a Ki value of 7 nM[1]. Exicorilant (CORT 125281) has potential to overcome adiposity, glucose intolerance and dyslipidaemia[2].

Exicorilant (CORT 125281) is a selective and oral active glucocorticoid receptor (GR) antagonist, with a Ki value of 7 nM[1]. Exicorilant (CORT 125281) has potential to overcome adiposity, glucose intolerance and dyslipidaemia[2].

Exicorilant (CORT 125281) is a selective and oral active glucocorticoid receptor (GR) antagonist, with a Ki value of 7 nM[1]. Exicorilant (CORT 125281) has potential to overcome adiposity, glucose intolerance and dyslipidaemia[2].

EXO1 Human Pre-designed siRNA Set A contains three designed siRNAs for EXO1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

EXO5 Human Pre-designed siRNA Set A contains three designed siRNAs for EXO5 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

EXOC1 Human Pre-designed siRNA Set A contains three designed siRNAs for EXOC1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

EXOC2 Human Pre-designed siRNA Set A contains three designed siRNAs for EXOC2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

EXOC3 Human Pre-designed siRNA Set A contains three designed siRNAs for EXOC3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

EXOC4 Human Pre-designed siRNA Set A contains three designed siRNAs for EXOC4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.